Skip to content
Home
Modalities
Made Scientific Team

T Cell Manufacturing & Development

T cell programs carry a distinct manufacturing risk profile: variable patient-derived starting material, transduction efficiency that has to hold consistent at scale, and phenotype shifts during expansion that surface late. Autologous workflows add the pressure of patient-specific timelines and chain of identity across concurrent campaigns.

We work with sponsors to engineer process control and biological complexity together from the start, rather than correcting for them downstream.

Our Approach

What differentiates our approach:

  • Platform processes built around T cell biology, transduction performance, and patient-specific scheduling
  • Stage-appropriate process and analytical strategies that evolve with your program and support comparability across phases
  • Integrated development, manufacturing, quality, and regulatory teams operating in one framework, for fewer handoffs and less rework
  • Dedicated cleanroom suites, automated bioprocessing, and in-house QC, structured for clinical progression and commercial supply

Services

From isolation through cryopreservation, Made Scientific supports the full T cell manufacturing lifecycle:

  • Autologous and allogeneic T cell isolation, activation, transduction, and expansion from pre-clinical through commercial GMP
  • Viral (LVV, RVV, AAV) and non-viral gene transfer (transposon, mRNA, LNPs)
  • Closed-system expansion with in-process controls and potency assays
  • GMP drug substance and drug product manufacturing; commercial-scale cryopreservation
  • Lot release, stability, and QC testing including vector copy number, RCL/RCR, identity, purity, safety

Our Capabilities

We support T cell programs with stage-appropriate development, GMP manufacturing, and quality systems designed to manage biological variability and enable confident clinical progression.

icon_Manufacturing Platforms_color

Manufacturing Platforms

Accelerate your T cell therapy with pre-validated platform processes designed for speed, quality, and regulatory readiness.

  • Standardized workflows for T cell isolation, activation, gene modification, and expansion
  • Pre-existing master batch records, SOPs, and trained manufacturing personnel
  • Reduce your path to IND by up to 70% compared to traditional development timelines
  • Flexible platforms supporting CAR-T, TCR-T, and next-generation engineered T cell products
icon_Process Analytical Dev_color

Process & Analytical Development

Optimize your T cell manufacturing process from early feasibility through commercial-scale production.

  • DoE-driven optimization of critical process parameters for transduction, expansion, and harvest
  • Viral and non-viral gene delivery development including lentiviral, retroviral, and electroporation methods
  • Analytical method development and validation for identity, potency, purity, and safety
  • Seamless technology transfer from development to GMP manufacturing
icon_GMP NonGMP Manufacturing_color

GMP and Non-GMP Manufacturing

Scalable T cell manufacturing in purpose-built facilities designed for both autologous and allogeneic programs.

  • ISO 7 cleanrooms compliant with US FDA and EU Annex 1 requirements
  • Automated and semi-automated bioprocessing across closed and functionally-closed expansion platforms
  • Electronic batch records and full process traceability across all manufacturing campaigns
  • Non-GMP manufacturing services for early-stage development and process optimization studies
icon_Aseptic Fill Finish_color0

Aseptic Fill & Finish

GMP-compliant formulation and filling tailored to the unique requirements of T cell products.

  • Cryopreservation with optimized cryoprotectant formulations and controlled-rate freezing
  • Semi-automated aseptic filling into cryovials and cryobags
  • Automated cell washing, formulation, and filling on closed-system platforms
  • Cold-chain handling and validated shipping to support time-sensitive autologous workflows
icon_QC Testing_v2

Quality Control Testing

Comprehensive release testing and stability programs built for the complexity of engineered T cell therapies.

  • Flow cytometry, qPCR/ddPCR, ELISA, and cell-based potency assays specific to T cell products
  • Rapid microbiological methods for sterility, mycoplasma, and endotoxin to support accelerated release
  • Long-term, accelerated, and shipping stability studies with cryopreservation assessments
  • Phase-appropriate method qualification and validation aligned with ICH Q2(R1) guidelines
icon_Regulatory_v2

Regulatory Consulting

Strategic regulatory guidance tailored to the evolving landscape of T cell-based therapies.

  • IND authoring support and CMC strategy for Modules 2 and 3
  • Pre-IND and FDA/EMA meeting preparation and submission support
  • Designation assessments for RMAT, Breakthrough Therapy, Fast Track, and Orphan Drug pathways
  • Global regulatory coordination across US, EU, and additional markets

Explore the Platform Behind Faster CAR-T

Speed in CAR-T manufacturing comes from two things working together: a process built to remove steps, and the enabling technology that makes single-step transfer possible. Start with either.

In their first collaboration study, Made Scientific evaluated Syenex's RapidCell™ Lentiviral Vector as the enabling technology for a consolidated, single-step CAR-T manufacturing workflow. The results demonstrate measurable advantages in transduction efficiency, CAR+ cell yield, and process simplicity — establishing RapidCell™ as a strong candidate within Made Scientific's MadeFast™ platform.

Key findings

  • 97%+ CAR transduction in unfractionated PBMCs without CD4/CD8 enrichment
  • 30% more viable CAR+ cells at harvest versus conventional methods at MOI = 1 — supporting reduced vector consumption and lower cost per dose
  • ≥97% viability across all conditions at Day 8 harvest (reaching 97–99.5%)
  • Balanced CD4/CD8 ratios preserved across all experimental conditions
  • Higher per-cell CAR density (MFI) than control vector at every MOI tested
Read the White Paper
Untitled design (5)

Single-step manufacturing depends on the right enabling technology. Our partnership with Syenex brings RapidCell™ Rapid-T LVV into the platform — purpose-built lentiviral delivery for T cells that supports a faster, cleaner path from vector to product.

Explore the Partnership
Syenex-Logo

What Sets Made Scientific Apart

Ready Made T Cell Platform

Pre-existing MBRs, validated methods, and qualified supply chains. PD teams operate within the same framework as GMP, QC, and regulatory, so the handoff from development to manufacturing carries fewer surprises.

Chain of Identity and Custody by Design

COI and COC are built into execution design from day one — embedded in workflows, reinforced through systems, standardized through operator training. Not treated as a documentation layer.

Integrated Team, Fewer Handoffs

Development, manufacturing, quality, and regulatory operate within a single framework. Programs move from PD to GMP without the rework that comes from vendor transitions or organizational handoffs.

GC Corporation Backing

The agility of a specialist CDMO with the global expertise and resources of GC Corporation, a South Korean pharmaceutical and biotechnology leader — providing long-term stability and investment in infrastructure, capabilities, and talent.

T Cell Manufacturing Insights

Perspectives from Made Scientific's team on the operational, technical, and strategic decisions that shape T cell manufacturing outcomes.

Post 3

De-Risking Autologous T Cell Manufacturing Operations

From process design to patient delivery, success depends on how the manufacturing system operates under real conditions. Read how programs manage the operational realities of autologous manufacturing.

Read Article
Post 3_ Process Development for Engineered T Cells_ Designing for GMP Early

Process Development for Engineered T Cells: Designing for GMP Early

Gene modification, expansion, and analytical strategy — the development decisions that shape whether a T cell process transitions cleanly into GMP or carries rework forward.

Read Article
Post 4

Scaling T Cell Manufacturing Starts With Infrastructure Built for Execution

Closed systems, traceability, GMP readiness — scaling autologous manufacturing depends on infrastructure and systems that support consistent execution across concurrent patient campaigns.

Read Article

Made is easy to work with. We’ve got your back.

We work as an extension of your team. T cell programs rarely move in a straight line, so our engagement models are designed to flex with your timelines as data evolves and patient demand scales.

Traditional & Dedicated Service

All Clients

We provide turnkey solutions with ready-made platform processes or purpose-built technology transfer, plus dedicated capacity models to secure your supply chain.

For T cell programs, this spans isolation, activation, gene modification, and expansion through drug product release.

Hybrid Client-In-Plant Operations

Mid-to-Late Stage Clients

We get you started, then step back. Cutting-edge labs, cleanrooms, and equipment are available in shared or dedicated settings, supported by specialized experts.

Ideal for T cell sponsors who want hands-on oversight of manufacturing while leveraging established GMP infrastructure.

Custom Build-outs & Partnerships

Late-Stage and Commercial Clients

We collaborate on custom lab, cleanroom, warehousing, and cold-chain solutions tailored to your workflow and spatial needs in our expansion areas.

Designed for T cell programs approaching commercial scale with dedicated throughput and patient-campaign requirements.

Made Scientific - Interactive Background

Ready to Discuss Your T Cell Program?

Whether you're advancing a CAR-T, TCR-T, or next-generation engineered T cell therapy — from early development through GMP manufacturing and beyond — Made Scientific's team is ready to help you move forward with confidence.

MadeMay2026-GMP_097